MetaVia Inc. (MTVA)
NASDAQ · Manufacturing · Pharmaceutical preparations
MTVA price, last 12 months
Key stats
- Previous close
- $1.06
- Open
- $1.09
- Day range
- $1.06 – $1.15
- 52-week range
- $0.9661 – $13.42
- Volume
- 60.6K
- Avg volume (20 days)
- 199.6K
- Market cap
- $8.6M
Performance
Technicals and fundamentals
About MetaVia Inc.
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $8.6M